What can replace digoxin in heart failure treatment?
Digoxin is sometimes used in heart failure, usually to help control symptoms in certain patients and/or reduce hospitalizations. Alternatives depend on the patient’s heart failure type (with reduced vs preserved ejection fraction) and the underlying rhythm issue (especially atrial fibrillation). Common non-digoxin options include guideline-directed heart failure medicines such as:
- Beta blockers (e.g., carvedilol, metoprolol succinate, bisoprolol)
- Renin-angiotensin system drugs (ACE inhibitors, ARBs, and ARNI such as sacubitril/valsartan)
- Mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone)
- SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)
- Diuretics (for symptom relief of fluid overload, such as furosemide or torsemide)
For some patients with heart failure plus atrial fibrillation, clinicians may also use other rate-control or rhythm strategies rather than digoxin, depending on blood pressure, heart rate targets, and comorbidities.
Are there digoxin-free options for heart failure with reduced ejection fraction (HFrEF)?
For HFrEF, many patients can be managed without digoxin by using combinations of therapies that have shown survival and hospitalization benefits. Typical “core” options include ARNI/ACEi/ARB, beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, with diuretics added as needed for congestion.
In practice, digoxin is more likely to be used when symptoms persist or when heart rate control is needed in the setting of atrial fibrillation. If you are looking specifically to avoid digoxin, the main question to ask your clinician is which of these disease-modifying therapies you are already on, and whether adjustments could make digoxin unnecessary.
What about heart failure with preserved ejection fraction (HFpEF)?
HFpEF has fewer therapies with clear, broad benefits compared with HFrEF, but non-digoxin approaches still matter. Treatment often focuses on:
- Controlling blood pressure
- Managing volume status with diuretics when there is congestion
- Treating contributing conditions (atrial fibrillation, ischemia, obesity, sleep apnea, diabetes)
SGLT2 inhibitors are used in HFpEF in many clinical settings based on trial evidence. Digoxin is not usually a core HFpEF treatment unless there is another specific reason (such as atrial fibrillation rate control).
If the goal is heart rate control (especially with atrial fibrillation), what are the alternatives?
Digoxin is often chosen for rate control when heart rate is difficult to manage or when beta blockers/calcium channel blockers aren’t tolerated. Alternatives clinicians may use include:
- Beta blockers for rate control
- Non-dihydropyridine calcium channel blockers (diltiazem or verapamil) in selected patients
- Other rhythm-control strategies depending on the patient’s overall status and duration of atrial fibrillation
The right choice depends heavily on blood pressure, heart function, and whether the patient has reduced versus preserved ejection fraction.
What side effects and risks make people switch off digoxin?
A common reason to consider alternatives is digoxin’s narrow safety window and the risk of toxicity, especially with certain conditions and interacting drugs. Risk can rise with:
- Kidney impairment (reduced clearance)
- Low potassium or magnesium (increases risk of arrhythmias)
- Drug interactions that raise digoxin levels
- Dehydration or over-diuresis (can shift electrolytes)
If these risks apply, clinicians may prefer other heart failure medications (and different rate-control options when atrial fibrillation is present).
When are alternatives less effective or not appropriate?
The “best” digoxin alternative is not the same for every patient. Alternatives may be limited by:
- Kidney function (relevant for several meds and for diuretics/electrolyte balance)
- Blood pressure tolerance (some disease-modifying drugs and beta blockers may lower BP)
- Bradycardia or conduction disease (rate-control meds may not be safe)
- Specific heart failure subtype and comorbidities
Your clinician typically matches medication choice to your ejection fraction, blood pressure, kidney function, rhythm status, and symptom pattern (congestion vs other symptoms).
Are there device or procedure options instead of digoxin?
Yes, for some patients. Depending on the cause and severity of heart failure and conduction/rhythm issues, clinicians may consider:
- Cardiac resynchronization therapy (CRT) for certain electrical dyssynchrony patterns
- Implantable cardioverter-defibrillator (ICD) for selected patients
- Catheter procedures for atrial fibrillation in selected cases
These do not “replace” digoxin one-to-one, but they can reduce the need for certain symptom or rhythm approaches in appropriate candidates.
---
If you share 3 details, I can narrow the alternatives
What type of heart failure do you have (HFrEF or HFpEF, or your ejection fraction), do you have atrial fibrillation, and what is the reason you want to avoid digoxin (side effects, toxicity risk, or lack of benefit)?